SCM
TVTX icon

Stonepine Capital Management’s Travere Therapeutics TVTX Stock Holding History

Stonepine Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-132,005
Closed -$2.97M – 24
2023
Q1 		$2.97M Buy
+132,005
New +$2.81M 1% 17
2019
Q4 		– Sell
-29,675
Closed -$344K – 29
2019
Q3 		$344K Buy
+29,675
New +$490K 0.33% 23

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Stonepine Capital Management's TVTX Position: Q2 2023 in Review

Stonepine Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 132,005 shares — an estimated $2.97M sold.

Stonepine Capital Management first reported a position in TVTX in Q3 2019 and held it in 2 quarters. The position peaked at $2.97M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

  • Stonepine Capital Management reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Stonepine Capital Management sold 132,005 Travere Therapeutics shares in Q2 2023, an estimated $2.97M.
  • Stonepine Capital Management first reported a position in Travere Therapeutics in Q3 2019 and held it in 2 quarters.
  • Stonepine Capital Management's Travere Therapeutics position peaked at $2.97M in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Stonepine Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.